Karyopharm Therapeutics (NASDAQ:KPTI) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a report published on Thursday morning,Benzinga reports. They currently have a $7.00 target price on the stock.

Other research analysts also recently issued research reports about the stock. Piper Sandler upped their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Royal Bank of Canada reiterated an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a research report on Monday, February 10th. Finally, StockNews.com lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Karyopharm Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Stock Performance

NASDAQ:KPTI opened at $0.61 on Thursday. Karyopharm Therapeutics has a 12 month low of $0.53 and a 12 month high of $1.70. The company’s 50-day moving average price is $0.66 and its two-hundred day moving average price is $0.76.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Wednesday, February 19th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.02. The business had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. As a group, analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in KPTI. Velan Capital Investment Management LP acquired a new position in Karyopharm Therapeutics during the 4th quarter valued at about $27,000. Focus Partners Wealth acquired a new position in Karyopharm Therapeutics in the fourth quarter valued at approximately $31,000. TD Waterhouse Canada Inc. acquired a new position in Karyopharm Therapeutics in the fourth quarter valued at approximately $32,000. Two Sigma Advisers LP lifted its stake in shares of Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after purchasing an additional 45,400 shares during the period. Finally, Opti Capital Management LP acquired a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at $85,000. 66.44% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).